Cargando…
Benefit–risk evaluation: the past, present and future
In the last two decades there has been a shift in the approach to evaluating the benefit–risk (BR) profiles of medicinal products from an unstructured, subjective, and inconsistent, to a more structured and objective, process. This article describes that shift from a historical perspective; the past...
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
SAGE Publications
2019
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6712756/ https://www.ncbi.nlm.nih.gov/pubmed/31489173 http://dx.doi.org/10.1177/2042098619871180 |